Abstract

The rapid evolution of glucagon-like peptide-1 (GLP-1) receptor agonists has transformed the therapeutic landscape of obesity. However, with the expiration of key patents such as semaglutide in 2026 and the anticipated entry of generic competitors, the market is entering a phase of commoditization characterized by significant price compression and expanded access. Despite their efficacy, GLP-1 therapies are associated with adverse events, lean mass loss, and substantial rates of discontinuation and weight regain. These limitations underscore the need for complementary strategies that address long-term metabolic health.

This presentation will highlight a comprehensive framework for Bioxentra Life Sciences, Inc., a nutraceutical-based metabolic companion platform designed to enhance GLP-1 therapy, improve tolerability, and support long-term weight maintenance. We integrate clinical evidence, mechanistic biology, and financial modeling to demonstrate how such a platform can play a pivotal role in the next generation of obesity treatment. The analysis suggests that Bioxentra can achieve scalable growth, strong unit economics, and significant return on investment, positioning it as a potential leading force in the evolving obesity ecosystem.

Bioxentra Life Sciences, Inc. is a life sciences company dedicated to advancing human health through the discovery and development of science-based nutraceuticals and bioactive compounds,The Company focuses on the intersection of neuroscience and metabolism, leveraging biological pathways such as IGF-1 and related signaling mechanisms to support cognitive functions, metabolic health, and healthy aging, Bioxentra’s approach bridges fundamental biology and practical health solutions, translating scientific insights into safe, effective, and accessible nutritional interventions designed to optimize healthspan and quality of life.

Dr. Lloyd L. Tran is a distinguished scientist with over 25 years of experience in drug discovery and business development within the pharmaceutical industry, He currently serves as the Chairman and Chief Executive Officer of Biomed Industries, Inc., headquartered in San Jose, California, Biomed Industries, Inc. operates several subsidiaries, including Biomed Pharmaceutical, Inc., NeuroActiva, Inc., Biomed Green, LLC, MedAware Systems, Inc., and Biomed AI, LLC